BRD9 and cancer: One of the first selective inhibition studies focused on BRD4 [113], a BRD9 paralog and BRD-containing protein family member with epigenetic mediatory activities and known roles in cancers, including chronic lymphocytic leukemia [114] and human squamous carcinoma [115].